Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a 1,5-benzodiazepine with anxiolytic and anticonvulsant properties. Unlike 1,4-benzodiazepines (e.g., diazepam), it has a more favorable side-effect profile regarding sedation and respiratory depression at therapeutic doses.
## Primary Indications
* Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS).
* Off-label: Treatment of refractory epilepsy, anxiety disorders.
## Adult Dosing
* **Initial:** 10 mg/day orally in divided doses.
* **Titration:** Increase at weekly intervals based on clinical response and tolerability.
* **Maintenance:** Generally 20-40 mg/day. Doses >40 mg/day have been studied but require close monitoring.
## Pediatric Dosing (≥2 years)
* **Weight-based:** Total daily dose is based on body weight.
* **≤30 kg:** Start 5 mg/day; may titrate up to 20 mg/day.
* **>30 kg:** Start 10 mg/day; may titrate up to 40 mg/day.
* *Note:* Dosing frequency is typically twice daily (BID).
## Dose Adjustments
* **Hepatic Impairment:** Reduce starting dose by 50% and titrate more slowly. Use with caution in severe impairment.
* **Renal Impairment:** No standard adjustment required, but use caution as active metabolites may accumulate.
* **CYP2C19 Poor Metabolizers:** Active metabolite (N-desmethylclobazam) concentrations may be 5-fold higher; initiate at 50% of the recommended dose and titrate cautiously.
## Contraindications
* Known hypersensitivity to clobazam.
* Severe hepatic impairment.
* Concomitant use with opioids (increases risk of profound sedation, respiratory depression, coma, and death).
## Adverse Effects
* **Common:** Somnolence, sedation, fever, lethargy, drooling (sialorrhea), constipation, ataxia.
* **Serious:** Severe dermatological reactions (SJS/TEN), respiratory depression, physical dependence/withdrawal symptoms, suicidal ideation.
## Key Drug Interactions
* **CNS Depressants:** Enhances sedation (includes alcohol, opioids, barbiturates).
* **CYP2C19 Inducers/Inhibitors:** Strong inhibitors (e.g., fluconazole, fluvoxamine) significantly increase clobazam exposure.
* **CYP2D6 Substrates:** Clobazam metabolites may inhibit CYP2D6; monitor patients taking medications like dextromethorphan or paroxetine.
* **Hormonal Contraceptives:** May decrease the effectiveness of estrogen-containing contraceptives.
## Monitoring
* **Baseline:** Baseline weight, hepatic/renal function.
* **Ongoing:** Monitor for behavioral changes, signs of depression, respiratory status (especially when combined with other CNS depressants), and seizure frequency.
* **Acute:** Monitor for skin rashes (SJS/TEN) upon initiation.
## Clinical Pearls
* **Withdrawal Risk:** Abrupt discontinuation can precipitate status epilepticus; taper doses gradually over several weeks.
* **Tolerance:** Tolerance to the antiseizure effects may develop over time.
* **Administration:** Tablets can be crushed and mixed with applesauce. Suspension should be shaken well.
* **Clinical Protocol:** Individual institutional protocols may vary regarding titration speed and maximum daily dosing; always verify against local hospital formulary or epilepsy center guidelines.
***
**Educational Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Prescribing information, drug interactions, and safety warnings change frequently. Always consult the most current official FDA-approved labeling (Package Insert) or a reliable clinical decision support database (e.g., Lexicomp, Micromedex) before prescribing or administering medication.
